To the extent possible under law, AOP-Wiki has waived all copyright and related or neighboring rights to KER:904
N/A, Mitochondrial dysfunction 1 leads to Impaired, Proteostasis
Key Event Relationship Overview
AOPs Referencing Relationship
|AOP Name||Adjacency||Weight of Evidence||Quantitative Understanding||Point of Contact||Author Status||OECD Status|
|Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits||adjacent||Moderate||Low||Andrea Terron (send email)||Open for citation & comment||WPHA/WNT Endorsed|
|Mitochondrial complex inhibition leading to liver injury||adjacent||Not Specified||Not Specified||Wanda van der Stel (send email)||Under development: Not open for comment. Do not cite|
Life Stage Applicability
Key Event Relationship Description
In any cell type, including neurons, the protein homeostasis (proteostasis) plays a key role in cellular functions. There are two major systems involved in the removal of damaged cellular structures (e.g. defective mitochondria) and misfolded or damaged proteins, the ubiquitin-proteasome system (UPS) and the autophagy–lysosome pathway (ALP). These processes are highly energy demanding and highly susceptible to oxidative stress. Upon mitochondrial dysfunction UPS and ALP functions are compromised resulting in increased protein aggregation and impaired intracellular protein/organelles transport (e.g. Zaltieri et al., 2015; Song and Cortopassi, 2015; Fujita et al., 2014; Esteves et al., 2011; Sherer et al., 2002).
Evidence Collection Strategy
Evidence Supporting this KER
The weight of evidence supporting the relationship between mitochondrial dysfunction and impaired proteostasis, including the impaired function of UPS and ALP that results in decreased protein degradation and increase protein aggregation is strong.
The biological relationship between Mitochondrial dysfunction and Impaired proteostasis (unbalanced protein homeostasis) that involves dysregulation of proteins degradation (misfolded or damaged) as well as removal of cell organelles is partly understood. Under physiological conditions, mechanisms by which proteostasis is ensured include regulated protein translation, chaperone assisted protein folding and functional protein degradation pathways. Under oxidative stress, the proteostasis function becomes burdened with proteins modified by ROS (Powers et al., 2009; Zaltieri et al., 2015). These changed proteins can lead to further misfolding and aggregation of proteins (especially in non-dividing cells, like neurons). Particularly in DA cells, oxidative stress from dopamine metabolism and dopamine auto-oxidation may selectively increase their vulnerability to CI inhibitors (such as rotenone) and cause additional deregulation of protein degradation (Lotharius and Brundin, 2002; Esteves et al., 2011). As most oxidized proteins get degraded by UPS and ALP (McNaught and Jenner, 2001), mitochondrial dysfunction and subsequent deregulation of proteostasis play a pivotal role in the pathogenesis of PD (Dagda et al., 2013; Pan et al., 2008; Fornai et al., 2005; Sherer et al., 2002). It is also well documented that increased oxidative stress changes the protein degradation machinery and leads to a reduction of proteasome activity (Lin and Beal, 2006; Schapira, 2006).
Uncertainties and Inconsistencies
- The exact molecular link from mitochondrial dysfunction to disturbed proteostasis is not known. It is not clear which is the oxidative modification that drives the process.
- The sequence of events taking place after inhibition of CI is not entirely clear (Zaltieri et al., 2015). Some studies suggest that induced oxidative stress leads to α-synuclein aggregation that triggers proteosomal dysfunction (Betarbet et al., 2006). Such order of events is suggested to take place in vivo (McNaught and Jenner, 2001). However, in other studies opposite sequence of events is proposed suggesting that first proteosomal dysfunction take place that leads to α-synuclein aggregation.
A vicious circle is observed here as α-synuclein aggregation potentiates proteosomal dysfunction and v/v. In this vicious cycle it is difficult to establish exact quantitative relationship of these two events.
- Whether α-synuclein is a substrate for proteasome remains controversial since both positive and negative data have been reported (Paxinou et al., 2001). Furthermore, polyubiquitination of α-synuclein, a prerequisite for 26S proteasomal degradation has yet to be reported (Stefanis et al., 2001). It is also not clear whether polyubiquitination of α-synuclein is necessary for its degradation. However, α-synuclein gets targeted by the UPS in the SHSY5Y neuroblastoma cell line. Phosphorylated α-synuclein gets targeted to mono- or di-ubiquitination in synucleinopathy brains (Hasegawa et al., 2002), but it is not clear if this modification can play any role in proteasomal degradation since monoubiquitination of proteins serves mainly as a signal for endocytosis or membrane trafficking.
- On the contrary to the increased α-synuclein levels observed in the midbrain, decreased α-synuclein levels were found in the cerebellums of PD patients when compared to controls, suggesting an imbalance of α-synuclein levels in different parts of the brain (Westerlund et al., 2008).
- Although mitochondrial alterations have been reported in PD patients (Ikawa et al., 2011) and disease models, it is not clear whether they represent a primary pathogenic mechanism. In particular, the critical interplay between mitochondrial dysfunction and oxidative stress, which has been widely reported in PD (Dias et al., 2013) and could constitute either a cause or a consequence of mitochondrial damage, hampers an effective comprehension of the above mentioned studies. Oxidative stress can constitute a bridge connecting mitochondrial dysfunction to the induction of α-synuclein misfolding, aggregation, and accumulation, but otherwise it may be also triggered by these latter events that in turn could induce mitochondrial alterations (Zhu and Chu, 2010; Dias et al., 2013).
- It is still unclear whether the involvement of α-synuclein in chronic MPTP toxicity reflects a physiological function for α-synuclein that has been activated in the wrong context, or whether α-synuclein produces an accidental pathogenicity that contributes to MPTP toxicity but is unrelated to the normal function of α-synuclein (Fornai et al., 2005).
- The inconsistent effects of MPP+ on autophagy (up or down regulation) are reported. It may be attributed to differences observed between immortalized cell lines and primary neurons, different timing or dose. While dysregulation of autophagy is always described, the direction is not clear. Further studies are required to clarify this issue.
- MPTP administration does not induce Lewy body formation (in contrast to rotenone) characteristic of PD, even after repeated injections (Drolet et al., 2004; Dauer et al., 2002).
- There is also controversy over whether the increase in autophagic markers is protective or, on the contrary, causative of neuronal death.
- MPP+ may have effects apart from CI inhibition, e.g., on microtubules but it is still unclear whether this is a primary effect. Indeed, MPP+ binds to microtubules in PC12 cells and inhibits their polymerization and stability (Cappelletti et al., 1999; Cappelletti et al., 2001).
- It is not clear whether microtubules disruption may be associated with α-synuclein aggregation since tubulin was shown to co-localize with α-synuclein in Lewy bodies. Furthermore, tubulin folding is dependent on ATP and GTP hydrolysis, and mitochondrial dysfunction with subsequent energy failure could trigger microtubules disruption. Cytoskeletal microtubule (MT) injury is likely to be responsible for altered rearrangement and movement of cell organelles, being a common feature of several neurodegenerative diseases including PD (Wade, 2009; Mattson et al., 1999).
- It is not clear whether rotenone could cause microtubules depolymerization in vivo and in vitro (Brinkley et al., 1974) by binding to the colchicine site on tubulin heterodimers (Marshall et al., 1978). Ren and Feng (2007) found that microtubule depolymerization induced by rotenone caused vesicle accumulation in the soma and kills neurons.
Known modulating factors
Known Feedforward/Feedback loops influencing this KER
Domain of Applicability
The ubiquitin proteasome system is highly conserved in eukaryotes, from yeast to human. Ubiquitin is a small (8.5 kDa) regulatory protein that has been found in almost all tissues of eukaryotic organisms. For instance, drosophila has been used as PD model to study the role of ubiquitin in α-synuclein induced-toxicity (Lee et al., 2009). Human and yeast ubiquitin share 96% sequence identity. Neither ubiquitin nor the ubiquitination machinery are known to exist in prokaryotes. Autophagy is ubiquitous in eukaryotic cells and is the major mechanism involved in the clearance of oxidatively or otherwise damaged/worn-out macromolecules and organelles (Esteves et al., 2011). Due to the high degree of conservation, most of the knowledge on autophagy proteins in vertebrates is derived from studies in yeast (Klionsky et al., 2007). Autophagy is seen in all eukaryotic systems, including fungi, plants, slime mold, nematodes, fruit flies and insects, rodents (i.e., laboratory mice and rats), and humans. It is a fundamental and phylogenetically conserved self-degradation process that is characterized by the formation of double-layered vesicles (autophagosomes) around intracellular cargo for delivery to lysosomes and proteolytic degradation.
Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM et al. 2010. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol. 67:1464–1472.
Ambrosi G, Ghezzi C, Sepe S, Milanese C, Payan-Gomez C, Bombardieri CR, Armentero MT, Zangaglia R, Pacchetti C, Mastroberardino PG, Blandini F. Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease. Biochim Biophys Acta. 2014 Sep;1842(9):1385-94.
Bai Y, Hajek P, Chomyn A, Chan E, Seo BB, Matsuno-Yagi A,Yagi T, Attardi G. 2001. Lack of complex I activity in human cells carrying a mutation in MtDNA-encoded ND4 subunit is corrected by the Saccharomyces cerevisiae NADH-quinone oxidoreductase (NDI1) gene. J. Biol. Chem. 276: 38808– 38813.
Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, et al. 2006. Intersecting pathways to neurodegeneration in Parkinson’s disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin–proteasome system. Neurobiol Dis. 22:404–20.
Betarbet R., Sherer T.B., Greenamyre J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol., 191 (Suppl.) (2005), pp. S17–S27
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 3:1301–6.
Borland MK, Trimmer PA, Rubinstein JD, Keeney PM, Mohanakumar KP, Liu L and Bennett JP. 2008. Chronic, low-dose rotenone reproduces lewy neurites found in early stages of Parkinson’s disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Molecular Neurodegeneration. 3,(1) 21.
Bove J, Martinez-Vicente M, and Vila M. 2011. Fighting neurodegeneration with rapamycin: Mechanistic insights. Nat. Rev. Neurosci. 12:437–452.
Brinkley BR, Barham SS, Barranco SC, and Fuller GM. 1974. Rotenone inhibition of spindle microtubule assembly in mammalian cells,” Experimental Cell Research. 85(1)41–46.
Brownlees J, Ackerley S, Grierson AJ. Jacobsen NJ, Shea K, Anderton BH, Leigh PN, Shaw CE, Miller CC. 2002. Charcot- Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport, Human Molecular Genetics, vol. 11, no. 23, pp. 2837–2844.
Calì T, Ottolini D, Negro A, Brini M. α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J Biol Chem. 2012 May 25;287(22):17914-29. doi: 10.1074/jbc.M111.302794. Epub 2012 Mar 27.
Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, and Greenamyre JT. 2009. “A highly reproducible rotenone model of Parkinson’s disease”. Neurobiology of Disease. 34(2) 279–290.
Cappelletti G, Maggioni MG, Maci R. 1999. Influence of MPP+ on the state of tubulin polymerisation in NGF-differentiated PC12 cells. J Neurosci Res. 56(1):28-35.
Cappelletti G, Pedrotti B, Maggioni MG, Maci R. 2001. Microtubule assembly is directly affected by MPP(+)in vitro. Cell Biol Int.25(10):981-4.
Chang DT, Honick AS, Reynolds IJ. 2006. Mitochondrial trafficking to synapses in cultured primary cortical neurons. J Neurosci. 26: 7035–7045.
Chen L, Jin J, Davis J, Zhou Y, Wang Y, Liu J, Lockhart PJ, Zhang J. 2007. Oligomeric α-synuclein inhibits tubulin polymerization. Biochem Biophys Res Commun. 356: 548–553.
Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. 2007. Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. J. Cell Sci. 120:4155–4166.
Cherra SJ,Kulich SM, Uechi G, Balasubramani M, Mountzouris J, Day BW, Chu CT. 2010. Regulation of the autophagy protein LC3 by phosphorylation. J. Cell Biol. 190:533–539.
Chiba Y., S. Takei, N. Kawamura, Y. Kawaguchi, K. Sasaki, S. Hasegawa-Ishii, A. Furukawa, M. Hosokawa, A. Shimada. Immunohistochemical localization of aggresomal proteins in glial cytoplasmic inclusions in multiple system atrophy. Neuropathol. Appl. Neurobiol., 38 (2012), pp. 559–571.
Chou AP, Li S, Fitzmaurice AG, Bronstein JM. 2010. Mechanisms of rotenone-induced proteasome inhibition. NeuroToxicology. 31:367–372.
Chu CT, Ji J, Dagda RK, Jiang JF, Tyurina YY, Kapralov AA, Tyurin VA, Yanamala N, Shrivastava IH, Mohammadyani D, Qiang Wang KZ, Zhu J, Klein-Seetharaman J, Balasubramanian K, Amoscato AA, Borisenko G, Huang Z, Gusdon AM, Cheikhi A, Steer EK, Wang R, Baty C, Watkins S, Bahar I, Bayır H, Kagan VE. 2013. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat. Cell Biol. 15(10):1197-205.
Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. 2009. Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to α-synuclein inclusions. Neurobiol Dis. 35(3):385-98.
Cole, N.B., Sciaky, N., Marotta, A., Song, J. & Lippincott-Schwartz, J. (1996) Golgi dispersal during microtubule disruption: regeneration of Golgi stacks at peripheral endoplasmic reticulum exit sites. Mol. Biol. Cell, 7, 631–650.
Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E. 2010. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of α-synucleinopathy. PLoS One 19;5(2):e9313.
Dadakhujaev S, Noh HS, Jung EJ, Cha JY, Baek SM, Ha JH, Kim DR. 2010. Autophagy protects the rotenone-induced cell death in α-synuclein overexpressing SH-SY5Y cells. Neurosci. Lett. 472:47–52.
Dagda RK, Banerjee TD and Janda E. 2013. How Parkinsonian Toxins Dysregulate the Autophagy Machinery. Int. J. Mol. Sci. 14:22163-22189.
Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M. 2007. Different species of α-synuclein oligomers induce calcium influx and seeding. The Journal of Neuroscience, 27(34):9220–9232.
Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, Hen R. 2002. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A. 99(22):14524-9.
Domingues AF, Arduíno DM, Esteves AR, Swerdlow RH, Oliveira CR, Cardoso SM. Mitochondria and ubiquitin-proteasomal system interplay: relevance to Parkinson's disease. Free Radic Biol Med. 2008 Sep 15;45(6):820-5.
De Vos KJ, Grierson AJ, Ackerley S, and Miller CCJ. 2008. Role of axonal transport in neurodegenerative diseases, Annual Review of Neuroscience. 31:151–173.
De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF, Brownlees J, Ackerley S, Shaw PJ, McLoughlin DM, Shaw CE, Leigh PN, Miller CC, Grierson AJ. 2007. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content”. Human Molecular Genetics. 16(22):2720–2728.
Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, Vila M. 2010. Pathogenic lysosomal depletion in Parkinson’s disease. J. Neurosci. 30:12535–12544.
Dias V, Junn E, and Mouradian MM. 2013. The role of oxidative stress in parkinson’s disease. Journal of Parkinson’s Disease. 3(4):461–491.
Drolet RE, Cannon JR, Montero L, and Greenamyre JT. 2009. Chronic rotenone exposure reproduces Parkinson’s disease gastrointestinal neuropathology. Neurobiology of Disease. 36(1):96–102.
Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL, 2004. Mice lacking α-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology. 25(5):761-9.
Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, and Sidhu A. 2006. α-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J. 20, 2302–2312.
Esposito A, Dohm CP, Kermer P, Bähr M, Wouters FS. 2007. α-synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol Dis 26:521–531.
Esteves AR, Arduíno DM, Silva DF, Oliveira CR, Cardoso SM. 2011. Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD. Parkinsons Dis. 2011:693761.
Feng J, 2006. Microtubule: a common target for Parkin and Parkinson's disease toxins, Neuroscientist. 12(6)469–476.
Filomeni G, Graziani I, de Zio D, Dini L, Centonze D., Rotilio G, Ciriolo MR. 2012. Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: Possible implications for Parkinson’s disease. Neurobiol. Aging. 33:767–785.
Follett J, Darlow B, Wong MB, Goodwin J, and Pountney DL. 2013. Potassium depolarization and raised calcium induces α-synuclein aggregates.. Neurotoxicity Research. 23(4)378–392.
Fornai F, Schlüter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Südhof TC. 2005. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitinproteasome system and _α-synuclein. PNAS. 102: 3413–3418.
Fujita KA, Ostaszewski M, Matsuoka Y, Ghosh S, Glaab E, Trefois C, Crespo I, Perumal TM, Jurkowski W, Antony PM, Diederich N, Buttini M, Kodama A, Satagopam VP, Eifes S, Del Sol A, Schneider R, Kitano H, Balling R. 2014. Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map. Mol Neurobiol. 49:88–102. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM. 2003. Initiation and synergistic fibrillization of tau and α-synuclein. Science. 300:636–640.
Goodwin J, Nath S, Engelborghs Y, Pountney DL. 2013. Raised calcium and oxidative stress cooperatively promote α-synuclein aggregate formation. Neurochemistry International. 62(5)703–711.
Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H. Lee VMY, Trojanowski JQ, Mann D, and Iwatsubo T. 2002. Phosphorylated R-synuclein is ubiquitinated in R-synucleinopathy lesions, J. Biol. Chem. 277:49071-49076.
Haskin J, Szargel R, Shani V, Mekies LN, Rott R, Lim GG, Lim KL, Bandopadhyay R, Wolosker H, Engelender S. AF-6 is a positive modulator of the PINK1/parkin pathway and is deficient in Parkinson's disease. Hum Mol Genet. 2013 May 15;22(10):2083-96.
Höglinger GU, Carrard G, Michel PP, Medja F, Lombès A, Ruberg M, Friguet B, Hirsch EC. 2003. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson’s disease. J. Neurochem. 86, 1297–1307.
Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M. 2011. “Evaluation of striatal oxidative stress in patients with Parkinson’s disease using [62Cu]ATSM PET” Nuclear Medicine and Biology. 38(7)945–951.
Jiang H, Cheng D, Liu W, Peng J, Feng J. 2010. Protein kinase C inhibits autophagy and phosphorylates LC3. Biochem. Biophys. Res. Commun.395:471–476.
Kawaguchi Y., J.J. Kovacs, A. McLaurin, J.M. Vance, A. Ito, T.P. Yao. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell, 115 (2003), pp. 727–738.
Kim I, Rodriguez-Enriquez S, and Lemasters JJ. 2007. Selective degradation of mitochondria by mitophagy. Archives of Biochemistry and Biophysics. 462(2)245–253.
Lee HJ, Khoshaghideh F, Lee F, and Lee SJ. 2006. Impairment of microtubule-dependent trafficking by overexpression of α-synuclein. European Journal of Neuroscience. 24(11)3153–3162.
Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ. 2002. Formation and removal of α-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem. 277:5411–5417.
Lim J, Kim HW, Youdim MB, Rhyu IJ, Choe KM, Oh YJ. 2011. Binding preference of p62 towards LC3-ll during dopaminergic neurotoxin-induced impairment of autophagic flux. Autophagy. 7:51–60.
Lin MT and Beal MF 2006.Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 443:787-95.
Liu K, Shi N, Sun Y, Zhang T, Sun X. 2013. Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice. Neurochem. Res. 38:201–207.
Lotharius J, and Brundin P. 2002. Pathogenesis of Parkinson’s disease: dopamine, vesicles and α-synuclein. Nat. Rev., Neurosci. 3, 932– 942.
Mader BJ, Pivtoraiko VN, Flippo HM, Klocke BJ, Roth KA, Mangieri LR, Shacka JJ. 2012. Rotenone inhibits autophagic flux prior to inducing cell death. ACS Chem Neurosci. 3:1063–1072.
Mandel S, Maor G, and Youdim MBH. 2004. Iron and α-synuclein in the substantia nigra ofMPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (−)-epigallocatechin-3-gallate. Journal ofMolecular Neuroscience.24(3)401–416.
Marshall LE, and Himes RH. 1978. “Rotenone inhibition of tubulin self-assembly,” Biochimica et Biophysica Acta. 543(4)590–594.
Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S. 1999. Cellular and molecular mechanisms underlying perturbed energymetabolismand neuronal degeneration in Alzheimer’s and Parkinson’s diseases. Annals of the New York Academy of Sciences. 893:154–175.
McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. 2003. Altered proteasomal function in sporadic Parkinson’s disease. Exp. Neurol. 179, 38– 46.
McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. 2002. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci. Lett. 326, 155–158.
McNaught KS, Jenner P. 2001. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci. Lett. 297, 191– 194.
Miki Y., F. Mori, K. Tanji, A. Kakita, H. Takahashi, K. Wakabayashi. Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions. Neuropathology, 31 (2011), pp. 561–568.
Miller KE, and Sheetz MP. 2004. “Axonal mitochondrial transport and potential are correlated,” Journal of Cell Science, vol. 117, no. 13, pp. 2791–2804.
Müftüoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G, Ogüs H, Dalkara T, Ozer N. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord. 2004 May; 19(5):544-8.
Nakata Y, Yasuda T, Fukaya M, Yamamori S, Itakura M, Nihira T, Hayakawa H, Kawanami A, Kataoka M, Nagai M, Sakagami H, Takahashi M, Mizuno Y, Mochizuki H. 2012. Accumulation of α-synuclein triggered by presynaptic dysfunction.The Journal of Neuroscience. 32(48):17186–17196.
Nath S, Goodwin J, Engelborghs Y, and Pountney DL. 2011. Raised calcium promotes α-synuclein aggregate formation. Molecular and Cellular Neuroscience. 46 (2):516–526.
Nogales E. 2000. Structural insights into microtubule function, Annual Review of Biochemistry, vol. 69, pp. 277–302.
Nonaka T, and Hasegawa M. 2009. A cellular model to monitor proteasome dysfunction by α-synuclein. Biochemistry. 48(33) 8014–8022.
Obashi K, and Okabe S. 2013 Regulation of mitochondrial dynamics and distribution by synapse position and neuronal activity in the axon. European Journal of Neuroscience. 38(3) 2350–2363, 2013.
Osna NA, Haorah J, Krutik VM, Donohue TM. Jr 2004. Peroxynitrite alters the catalytic activity of rodent liver proteasome in vitro and in vivo. Hepatology. 40:574–82.
Pal R, Monroe TO, Palmieri M, Sardiello M, Rodney GG. Rotenone induces neurotoxicity through Rac1-dependent activation of NADPH oxidase in SHSY-5Y cells. FEBS Lett. 2014 Jan 31;588(3):472-81.
Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W. 2009. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience. 164:541–551.
Pan T, Kondo S, Le W, Jankovic J. 2008. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain. 131, 1969-1978.
Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O'Sullivan GA, Pal A, Said J, Marsico G, Verbavatz JM, Rodrigo-Angulo M, Gille G, Funk RH, Reichmann H. 2012. Environmental toxins trigger PD-like progression via increased alphasynuclein release from enteric neurons in mice. Scientific Reports. 2, 898.
Pan-Montojo FJ, and Funk RHW. 2010. Oral administration of rotenone using a gavage and image analysis of α-synuclein inclusions in the enteric nervous system. Journal of Visualized Experiments, no. 44, article 2123.
Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VM. 2001. Ischiropoulos H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci.21(20):8053-61.
Payton JE, Perrin RJ, Clayton DF, and George JM. 2001. Protein-protein interactions of α-synuclein in brain homogenates and transfected cells. Molecular Brain Research. 95(1-2):138–145.
Powers ET1, Morimoto RI, Dillin A, Kelly JW, Balch WE. 2009.. Biological and Chemical Approaches to Diseases of Proteostasis Deficiency. Ann. Rev. Biochem 78: 959–91.
Qureshi HY and Paudel HK. 2011. Parkinsonian neurotoxin 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alphasynuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem 286:5055–5068.
Ren Y, and Feng J. 2007. Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism. Journal of Neurochemistry. 103(1)303–311.
Richter-Landsberg C, Leyk J. Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration. Acta Neuropathol. 2013 Dec;126(6):793-807.
Rideout HJ, Larsen KE, Sulzer D, Stefanis L. 2001.Proteasomal inhibition leads to formation of ubiquitin/a-synuclein-immunoreactive inclusions in PC12 cells. Journal of Neurochemistry. 78, 899±908.
Saha AR, Hill J, Utton MA, Asuni AA, Ackerley S, Grierson AJ, Miller CC, Davies AM, Buchman VL, Anderton BH, Hanger DP. 2004.Parkinson’s disease α-synuclein mutations exhibit defective axonal transport in cultured neurons. Journal of Cell Science. 117(7):1017–1024.
Saotome M, Safiulina D, Szabadkai G, Das S, Fransson A, Aspenstrom P, Rizzuto R, Hajnoczky G. 2008. Bidirectional Ca2þ-dependent control of mitochondrial dynamics by the Miro GTPase. Proc Natl Acad Sci 105: 20728–20733.
Sarkar S, Chigurupati S, Raymick J, Mann D, Bowyer JF, Schmitt T, Beger RD, Hanig JP, Schmued LC, Paule MG. 2014. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson’s disease mouse model. Neurotoxicology 44C:250–262.
Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: much more than mitophagy. Trends Neurosci. 2014 Jun;37(6):315-24.
Schapira AH. 2006. Etiology of Parkinson's disease. Neurology. 66:S10-23.
Seo BB, Nakamaru-Ogiso E, Flotte TR, Yagi T, Matsuno-Yagi A. 2002. A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. Mol. Ther. 6, 336–341.
Seo BB, Wang J, Flotte TR, Yagi T, Matsuno-Yagi A. 2000. Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells. J. Biol. Chem. 275, 37774–37778.
Shamoto-Nagai M, Maruyama W, Kato Y, Isobe K, Tanaka M, Naoi M, Osawa T. 2003. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res. 74:589–97.
Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. 2002. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 22(16):7006-15.
Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. 2003. Mechanism of toxicity in rotenone models of Parkinson’s disease. J Neurosci. 23: 10756–64.
Song L and Cortopassi G. 2015. Mitochondrial complex I defects increase ubiquitin in substantia nigra. Brain Res. 12;1594:82-91.
Stamer K, Vogel R, Thies E, Mandelkow E, and.Mandelkow EM. 2002 Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress,” Journal of Cell Biology. 156(6):1051–1063.
Stefanis L, Larsen KE, Rideout HJ, Sulzer D, and Greene LA. 2001. Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitindependent degradation system, loss of dopamine release, and autophagic cell death. Journal of Neuroscience, vol. 21, no. 24, pp. 9549–9560, 2001.
Sun F, Anantharam V, Latchoumycandane C, Kanthasamy A, Kanthasamy AG. 2005. Dieldrin induces ubiquitin-proteasome dysfunction in α-synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death. J Pharmacol Exp Ther. 315(1):69-79.
Szabadkai G, Simoni AM, Bianchi K, De Stefani D, Leo S, Wieckowski MR, Rizzuto R. 2006. Mitochondrial dynamics and Ca2þ signaling. Biochim Biophys Acta 1763: 442–449.
Szweda PA, Friguet B, Szweda LI. 2002. Proteolysis, free radicals, and aging. Free Radic Biol Med. 33:29–36.
Thomas B, Banerjee R, Starkova NN, Zhang SF, Calingasan NY, Yang L, Wille E, Lorenzo BJ, Ho DJ, Beal MF, Starkov A. Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal. 2012, 16(9):855-68.
Tristão FS, Amar M, Latrous I, Del-Bel EA, Prediger RD, Raisman-Vozari R. 2014. Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson’s disease. Neurotoxicity Research. 25(1) 24–32.
Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. 2011. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 10:1015–1025.
Wade RH. 2009. On and around microtubules: an overview. Molecular Biotechnology. 43(2) 177–191.
Wang XF, Li S, Chou AP, Bronstein JM. 2006. Inhibitory effects of pesticides on proteasome activity: implication in Parkinson’s disease. Neurobiol Dis. 23:198–205.
Westerlund M, Belin AC, Anvret A, Håkansson A, Nissbrandt H, Lind C, Sydow O, Olson L, Galter D. 2008.Cerebellar alpha-synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. FASEB J. 22(10):3509-14.
Wu F., Xu HD,_ Guan JJ, Hou YS, Gu JH, Zhen XC and Qin ZH. 2015 Rotenone impairs autophagic flux and lysosomal functions in Parkinsons's disease. Neuroscience. 284: 900–911.
Yi M, Weaver D, Hajnoczky G. 2004. Control of mitochondrial motility and distribution by the calcium signal: A homeostatic circuit. J Cell Biol 167: 661–672.
Yu WH, Dorado B, Figueroa HY, Wang L, Planel E, Cookson MR, Clark LN, Clark LN, Duff KE. 2009. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric α-synuclein. Am J Pathol. 175:736–747.
Yuan YH, Yan WF, Sun JD, Huang JY, Mu Z, Chen NH. 2015.The molecular mechanism of rotenone-induced α-synuclein aggregation: emphasizing the role of the calcium/GSK3β pathway. Toxicol Lett. 233(2):163-71.
Zaltieri M, Longhena F, Pizzi M, Missale C, Spano P, Bellucci A. 2015. Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? Parkinsons Dis. 2015:108029.
Zhang H, Duan C, Yang H. Defective autophagy in Parkinson's disease: lessons from genetics. Mol Neurobiol. 2015 Feb;51(1):89-104. doi: 10.1007/s12035-014-8787-5.
Zhu J and Chu CT. 2010. “Mitochondrial dysfunction in Parkinson’s disease,” Journal of Alzheimer’s Disease. 20(2):S325–S334.
Zhu JH, Gusdon AM, Cimen H, van Houten B, Koc E, Chu CT. 2012. Impaired mitochondrial biogenesis contributes to depletion of functional mitochondria in chronic MPP+ toxicity: Dual roles for ERK1/2. Cell Death Dis. 2012;3:e312.
Zhu JH, Horbinski C, Guo F, Watkins S, Uchiyama Y, Chu CT. 2007.Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am. J. Pathol. 170:75–86.